HOME >> MEDICINE >> NEWS
Four new us patents granted to Acrux for transdermal drug delivery

Acrux Limited (ASX: ACR), the Australian pharmaceutical company that specialises in products delivering therapeutic drugs through the skin, today announced that it has been granted four more US patents relating to its transdermal drug delivery technology. The four US patents provide additional protection for systemic delivery of drugs in specific therapeutic areas, namely analgesics (US patent number 6,916,486), hormones (6,923,983), anti-Parkinson's agents (6,929,801) and anti-emetics (6,916,487). These are "continuation in part" patents, related to Acrux's US patent number 6,818,226.

The new patents, which expire in February 2017, further extend the proprietary nature of Acrux's transdermal drug delivery technology for a number of products in the current pipeline. They provide protection for transdermal drug delivery systems, in the specific therapy areas, that consist of an effective amount of physiologically active agent (e.g. a therapeutic drug), a dermal penetration enhancer, which is a safe skin-tolerant ester sunscreen, and a volatile liquid. Acrux now has six patents granted in the USA.

Acrux CEO and Managing Director, Dr Igor Gonda said: "These new US patents provide additional protection for our products in our core areas of interest. Our patenting activity is at the heart of our business strategy to develop and commercialise patient-preferred patent-protected healthcare products for valuable global markets."


'"/>

Contact: Igor Gonda
61-383-790-100
Research Australia
26-Sep-2005


Page: 1

Related medicine news :

1. REVLIMID(R) granted approval by FDA for treatment of multiple myeloma
2. Acrux granted first grant in Europe, triggering payment from Lilly
3. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
4. Acrux completes enrollment in key phase 2 trial
5. Acrux and Oreganon further expand their collaboration
6. Acrux patent portfolio advances in USA
7. Acrux acquires rights to commercialise worlds first contraceptive spray
8. Acrux reports progress in development of Testosterone MD-Lotion(R) for men
9. DAYTRANA (methylphenidate transdermal system) significant reduces ADHD symptoms
10. Shires DAYTRANA(TM) transdermal patch approved by FDA for treatment of ADHD
11. Positive study results for methylphenidate transdermal system

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Four new patents granted Acrux for transdermal drug delivery

(Date:5/24/2013)... For the second consecutive year, Tabitha teamed ... to treat Tabitha Meals on Wheels clients to a ... than 400 meal recipients recently enjoyed a Runza Sandwich ... the rest of a well-balanced, nutritious meal provided by ... the Tabitha Meals on Wheels team,” said Renee Sjulin, ...
(Date:5/24/2013)... 24, 2013 Chronic Fatigue Syndrome has ... sufferers with unexplained fatigue lasting 6 months or longer. ... memory and concentration impairment, muscle and joint pain without ... un-refreshing sleep and malaise that lasts for more than ... known to be linked to insulin resistance. At a ...
(Date:5/24/2013)... The Lap Band Center now offers complementary consultation ... head doctor at The Lap Band Center, if you ... change for the better, it is time to consider ... risks that come with obesity and one way to combat ... , Obesity related diseases are no laughing matter, many ...
(Date:5/24/2013)... NS (PRWEB) May 24, 2013 Today ... the all-new online Itinerary Builder. , The redesigned ... easily create unique vacation itineraries on their computer or ... , The interactive tool allows users to fill ... then browse through and select their choice of vacation ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Wednesday, 15th May ... , Register to access webinar playback: http://bit.ly/10Rt0ZH ... of the financial markets. Across the globe and particularly in ... probably affect M&A activity . For dealmakers, understanding how ... and the ‘Tobin Tax’ affects your corner of the market ...
Breaking Medicine News(10 mins):Health News:Runza® Delivers Sandwiches, Draws Smiles from Tabitha Meals on Wheels Clients 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 2Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Announces New hCG Diet Plans to Promote Fast Weight Loss Shown to Reduce the Risk & Symptoms of Chronic Fatigue 3Health News:The Lap Band Center Announces That They Offer Complementary Consultation for First Time Patients 2Health News:The Lap Band Center Announces That They Offer Complementary Consultation for First Time Patients 3Health News:Create and Win the Perfect Halifax Getaway with the All-New Itinerary Builder 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 2Health News:Register to Access Webinar Playback - The Impact of Financial Regulation on M&A in 2013 3
(Date:5/23/2013)... 2013 3SBio Inc. (NASDAQ: ... China -based biotechnology company focused ... announced today that, at an extraordinary general meeting ... in favor of the proposal to authorize and ... merger dated February 8, 2013, among Decade Sunshine ...
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 Neurocrine ... Kevin Gorman , President and Chief Executive ... Bank 38 th Annual dbAccess Health Care Conference in ... Thursday, May 30 at 11:20 a.m. Eastern Time / 8:20 ... be accessed on the Company,s website at http://www.neurocrine.com . ...
(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering.  In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering.   A portion of the proceeds will ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4
Cached News: